V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Immunome Executive Compensation (FY25)

IMNM · Executive and director compensation, fiscal 2025 only

The paid brief on Immunome

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Data as of September 7, 2026Latest filing (8-K): June 12, 2026
2 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Immunome brief$1,500Get the executive brief
59 figures on this page: 58 cited to the filing that reported them, 1 calculated from figures it prints. See the citations
Chief executive, fiscal 2025
◇
Clay Siegall
Latest say-on-pay support
=
June 9, 2026
This company is not required to report a chief executive pay ratio.

More on Immunome

Five data products on this company. Each one is requested through the developer setup page.

Frequently asked questions

Answers drawn from the data on this page.
Who is Immunome's chief executive and what were they paid?
Clay Siegall, President, Chief Executive Officer and Chairman of the Board, received $7,682,601 in total compensation for fiscal 2025.
What was Immunome's say-on-pay result?
The say-on-pay proposal drew 98.4% support at the meeting held June 9, 2026 for fiscal 2025.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Clay Siegall
President, Chief Executive Officer and Chairman of the Board
◇——◇◇—◇◇
Max Rosett
Chief Financial Officer
◇——◇◇—◇◇
Robert Lechleider
Chief Medical Officer
◇——◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Clay SiegallOPTION——————◇
Max RosettOPTION——————◇
Robert LechleiderOPTION——————◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Robert LechleiderOption◇—◇—
Option◇—◇—
Option◇—◇—
Max RosettOption◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Clay SiegallOption◇—◇—
Option◇—◇—
Option◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Isaac Barchas, J.D
Lead independent director
◇—◇———◇
Carol Schafer
◇—◇———◇
James Boylan
◇—◇———◇
Sandra Swain, M.D
◇—◇———◇
Philip Wagenheim
◇—◇———◇
Clay Siegall, Ph.D and Jean-Jacques Bienaim served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 9, 2026=◇◇◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Immunome files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Immunome disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Immunome's disclosed peer group is defensible, who names Immunome back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
59 figures on this page: 58 cited to the filing that reported them, 1 calculated from figures it prints.
58 cited to the filing
1 calculated from the filing

Documents cited

  1. 0001193125-26-269383
  2. 0001140361-26-016685
    EXECUTIVE COMPENSATION · Fiscal Year 2025 Summary Compensation Table · Non-Employee Director Compensation · Outstanding Equity Awards at Fiscal Year End
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Immunome executive compensation, FY2025.” https://intel.velarion.ai/comp/IMNM (accessed 2026).
Short form: data: Velarion

The paid brief for Immunome

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
2 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Immunome and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy